Main objective: To quantify mumps transmission parameters in exposed individuals, comparing symptomatic and asymptomatic cases, to understand and model ongoing transmission; Secondary: to assess cellular immuunresponses in mumps exposed infected and…
ID
Source
Brief title
Condition
- Viral infectious disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Number of transmission events
Viral excretion patterns and immuun responses among symptomatic and
asymptomatic infected individuals
Secondary outcome
To gain insight into cross-reactive potential of mumps specific cellular immune
mechanisms to circulating vaccine type and non-vaccine type mumps strains
Background summary
To understand the implications for future control strategies, the recent
emergence of mumps among fully vaccinated populations offers an important
opportunity to collect essential data to understand the current transmission
parameters. In particular we need to understand the extent to which
asymptomatic people contribute to ongoing transmission. Also we want to explore
the role of cellular immune responses in shaping the current epidemic. Such
data are needed to understand transmission dynamics and estimate future burden
in the vaccinated population.
Study objective
Main objective: To quantify mumps transmission parameters in exposed
individuals, comparing symptomatic and asymptomatic cases, to understand and
model ongoing transmission; Secondary: to assess cellular immuunresponses in
mumps exposed infected and unfected vaccinated indivduals to improve
understanding of the current and future epidemic
Study design
The study consists of two parts, both observational. The main study involves a
case contact study in which transmission by symptomatically and by
asymptomatically infected subjects will be studied. In a secondary study among
a small group of subjects cellular immune mechanisms of cases and of not
infected, vaccinated contacts will be studied. Both parts will be executed
independently.
Study burden and risks
There are no direct benefits for individual participants. There is no expected
risk for the participants. The burden and risk of blood collection (fingerprick
as well as venous blood sampling) is considered to be low. The burden and risk
of saliva collection is considered to be negligible.
Postbus 1
3720 BA Bilthoven
NL
Postbus 1
3720 BA Bilthoven
NL
Listed location countries
Age
Inclusion criteria
Transmission part:
* Elegibilty of the contacts of an index case depends on the index case. The contacts of an index case are only eligible for participation when the index case has a laboratory confirmed mumps virus infection and when the index case belongs to a suitable social network.
* The suitability of the network will be assessed by the research team. A suitable network is one with a high chance of mumps transmission occurring. This will depend on the age and residential situation of the network. The research team will use descriptive epidemiological information from mumps transmission networks that occurred in 2010 and 2011.
* >= 16 years of age
* Inclusion of first ring contacts should be within 10 days of the first symptoms of mumps disease of the index case;Cellular immunity part:
• A mumps case is eligible for participation in the cellular immunity study as case when mumps virus infection has been laboratory confirmed, and when he/she is >=18 yrs of age.
• A control for the cellular immunity study is a person who has no evidence of a recent mumps infections, e.g. contacts from the transmission study with a negative clinical history and absence of a serological response, has been vaccinated against mumps in the past, and he/she is >=18 yrs of age.
Exclusion criteria
Transmission part:
- having mumps at the time of inclusion, or ever have had mumps in the past.
Cellular immunity:
- be or have been under immunosuppressive medical treatment, like cytostatics and prednisolons that might interfere with the results of the study (within the previous 3 months)
- have any known primary or secondary immunodeficiency, or bleeding disorder
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL37852.094.11 |